Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.45 |
| ▸ | MET | P08581 | 13/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12689584 | 0.88 | MET (0.59) | PIK3CDMETNQO2PDE4CPDE4D | |
| SCHEMBL13452995 | 0.76 | MET (0.52) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL16587175 | 0.65 | MET (0.57) | METNQO2PDE4CPDE4DPDE3B | |
| Savolitinib SCHEMBL12690037 | 0.61 | MET (1.00) | METNQO2PDE4CPDE4DPDE3B | |
| Savolitinib SCHEMBL12486932 | 0.61 | MET (1.00) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL30948875 | 0.61 | MET (0.70) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL31120431 | 0.60 | MET (0.69) | METNQO2PDE4CPDE4DPDE3B | |
| SCHEMBL19286558 | 0.60 | PIK3CD (0.53) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL31483058 | 0.60 | PIK3CD (0.71) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL15959838 | 0.59 | PIK3CD (0.61) | PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956218-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2018-05-01 | — | — | US | disclosed |
| US-20170027934-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-02-02 | — | — | US | disclosed |
| US-8987269-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2015-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027934-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | KCNJ11, NISCH, CYP4Z1 | PIK3CD 1653/4885MET 4578/4885NQO2 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.